KRIBIOLISA™ Semaglutide ELISA

Immunoassay for Quantitative estimation of Semaglutide in human serum and plasma. Semaglutide (trade name Ozempic) is a pharmaceutical drug in development by a Danish company Novo Nordisk for the treatment of type 2 diabetes. It is marketed by the name Ozempic. As a glucagon-like peptide-1 receptor agonist, it lowers the blood sugar level by increasing the production of insulin. It was discovered in 2012, by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide. Clinical trials were started in 2015, and phase 3 was completed in 2016. FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favor. It can be used as both injection-type or oral-type drug. About the kit: - Uses anti-idiotypic antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity. - Recovery rates are between 85 - 115% - Ready to use with a standard protocol with break-apart pre-coated wells - Validated as per US FDA guidelines for Bioassays - Optimized for matrix effects to ensure higher sensitivity. - Shelf life: 1 year The Semaglutide ELISA is a competitive immunoassay for the determination of Semaglutide. The anti-GLP-1 antibodies are coated on 96 well plate. A constant concentration of Biotinylated GLP-1 and varying concentration of unlabeled Semaglutide or sample compete for binding to anti-GLP-1 antibodies. Captured Biotinylated GLP-1 antibodies are subsequently bound by Streptavidin-HRP which produces a soluble colored product after addition of TMB substrate. The enzyme reaction is stopped by dispensing of stop solution into the wells. The optical density (OD) of the solution at 450 nm is inversely proportional to the amount of bound Semaglutide molecule present in standards or samples.